RxDoctor Payments Data

Meredith Larue, NP

Family · Round Rock, TXNPI 1871982165

Payments from drug & device makers

$3,841in general payments, 2019–2025

Across 175 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$638
  • Johnson & Johnson$489
  • Pfizer$260
  • Bayer$244
  • Urogen Pharma, Inc.$234
  • Dendreon Pharmaceuticals LLC$226
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$3,74197%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,841 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$121,419
Medicare patients
314
Services billed
4,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron37$33,130
Abiraterone Acetate11$16,433
Solifenacin Succinate58$3,611
Alfuzosin Hcl ErAlfuzosin Hcl129$2,914
Estradiol44$2,752
Tamsulosin Hcl187$2,751
Potassium Citrate ErPotassium Citrate20$2,629
Testosterone Cypionate23$1,711
Finasteride115$1,295
Oxybutynin Chloride ErOxybutynin Chloride16$453
NitrofurantoinNitrofurantoin Macrocrystal15$252
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$160
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim23$91
Amitriptyline Hcl17$89
Ciprofloxacin Hcl17$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$638$33,13037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →